Fabino Life Sciences has informed that in continuation of letter dated November 02, 2022 and pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Unaudited Financial Results set out in compliance with Accounting Standards (AS) for the Half Year ended September 30, 2022 , duly approved by the Board of Directors of the Company in their meeting held on November 09, 2022 together with Statement of Assets and Liabilities, Cash Flow and Limited Review Report thereon are enclosed.
The above information is a part of company’s filings submitted to BSE.